Prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F23%3A00013515" target="_blank" >RIV/00023736:_____/23:00013515 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1097/HS9.0000000000000846" target="_blank" >https://doi.org/10.1097/HS9.0000000000000846</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HS9.0000000000000846" target="_blank" >10.1097/HS9.0000000000000846</a>
Alternative languages
Result language
angličtina
Original language name
Prediction of nonrelapse mortality in patients with acute myeloid leukemia and acute lymphoblastic leukemia receiving allogeneic stem cell transplantation with posttransplantation cyclophosphamide-based graft versus host disease prophylaxis
Original language description
Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of established NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, and subsequently developed and validated a novel PTCY-specific NRM-risk model. Collectively, we developed an NRM-risk score for acute leukemia patients receiving PTCY that better predicted 2-year NRM compared with existing models, which might be applicable to the specific toxicities of high-dose cyclophosphamide.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
HemaSphere
ISSN
2572-9241
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
"art. no. E846"
UT code for WoS article
000940441700001
EID of the result in the Scopus database
2-s2.0-85148772038